AKT1 and renal cell carcinoma: The PI3K/Akt pathway is implicated in RCC treatment, where naringenin has been identified as a potent inhibitor of RCC cell proliferation by modulating Ki67 expression, inducing G2 cell cycle arrest, upregulating caspase-8, downregulating Bcl-2, enhancing PTEN expression to inhibit proliferation and induce apoptosis, and downregulating PI3K and p-AKT (Li L. et al., 2024).